Informations générales (source: ClinicalTrials.gov)
4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice (OBALPA)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
juin 2013
décembre 2016
29 juin 2024
The management of patients with Obstructive Chronic BronchoPneumopathy (OCBP) is based on
a progression of therapeutic options and on a sensitization to physical activity.
For these patients selected on OCBP stage 2, the treatment options include Long Acting
Beta-Agonist Bronchodilator (LABA) or Long Acting Muscarinic Antagonist Anticholinergic
(LAMA) or both (LAMA+LABA).
The purpose of this study is to observe in common clinical practice the benefit of
physical activity on quality of life, dyspnoea and walking distance for these patients
under treatment (LABA and/or LAMA) and to determine whether these 3 medical strategies
(LABA/LAMA/LABA+LAMA) benefit from physical activity.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospices Civils de Lyon - 69004 - Lyon - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patients with Obstructive Chronic BronchoPneumopathy stage ≥ 2.
- Patients under treatment with LABA or LAMA or LABA+LAMA since at least 1 month.
- VEMS/CVF<70%
- VEMS<80%
- Patients without regular physical activity and without physical activity program
since 1 year.
- Patients with Obstructive Chronic BronchoPneumopathy stage ≥ 2.
- Patients under treatment with LABA or LAMA or LABA+LAMA since at least 1 month.
- VEMS/CVF<70%
- VEMS<80%
- Patients without regular physical activity and without physical activity program
since 1 year.
- Patients under treatment with LABA + inhaled Corticoids.
- Contraindication to physical activity.
- Patients with previous history of respiratory exacerbations.